Clinical Trials
FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer
FDAFDA What's New: Drugs

The Food and Drug Administration (FDA) has granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.), a kinase inhibitor indicated for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors demonstrate HER2 (ERBB) alterations.
Key Takeaways
- The FDA has granted accelerated approval to the kinase inhibitor sevabertinib (Hyrnuo) for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer harboring HER2 (ERBB) alterations.
Read the original sourceFDA What's New: Drugs
